Etex Corporation – Trademark Portfolio

Entity Type: 03

Etex Corporation holds 30 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 23 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include ETEX, BETA-BSM, CARRIGEN, GAMMA-BSM, and EQUIVABONE. The owner is based in Cambridge, MA.

38 Sidney Street

Cambridge, MA 02139

30 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Page 1 of 2 (30 results)

Trademark Classifications

Etex Corporation's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (23 filings)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Etex Corporation have?

Etex Corporation has 30 U.S. trademarks filed with the USPTO. Of these, 6 registered, 20 abandoned, 4 cancelled.

What trademark classes does Etex Corporation file in?

Etex Corporation files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Etex Corporation's most well-known trademarks?

Etex Corporation's registered trademark portfolio includes well-known marks such as ETEX, BETA-BSM, CARRIGEN, GAMMA-BSM, and EQUIVABONE. These are among 6 currently registered trademarks in the portfolio.

What is Etex Corporation's trademark registration success rate?

Etex Corporation has a 20% trademark registration rate, with 6 out of 30 resolved applications resulting in successful registration. Currently, 0 applications are pending review.